St Stephens Aids Trust
Quick facts
Marketed products
- Darunavir ritonavir · Infectious Disease / Virology
Darunavir is a protease inhibitor that blocks HIV protease, preventing viral replication, while ritonavir acts as a pharmacokinetic booster to increase darunavir levels. - Darunavir, Ritonavir and Rilpivirine · Infectious Disease / Virology
This combination inhibits HIV protease and reverse transcriptase to block viral replication at multiple steps. - Dolutegravir, efavirenz, efavirenz/emtricitabine/tenofovir · Infectious Disease / Virology
These are antiretroviral drugs that inhibit HIV replication through different mechanisms: dolutegravir blocks integrase, efavirenz inhibits reverse transcriptase, and the combination tablet inhibits both reverse transcriptase and blocks viral entry. - Eviplera® · Infectious Disease / Virology
Eviplera is a fixed-dose combination of three antiretroviral drugs that work together to suppress HIV replication by inhibiting reverse transcriptase and integrase enzymes. - Tivicay · Immunology
- Triumeq · Other
Phase 1 pipeline
- Dolutegravir, Elvitegravir and Cobicistat
- Ezetimibe and raltegravir
- Raltegravir and ezetimibe
- Rezolsta · Other
- Rifinah or local generics
- TMC125 once daily
- TMC125 twice daily
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: